Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan versus placebo in late-stage ADPKD with CKD
NL-OMON41925Phase 3Active, not recruiting
- Sponsor
- Otsuka America Pharmaceutical
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) and chronic kidney disease (CKD) comparing Tolvaptan with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2015; status: active, not recruiting.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON41925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41925.